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Introduction
Phenylketonuria (PKU) is an autosomal recessive inborn
error of phenylalanine (Phe) metabolism caused by
mutations in phenylalanine hydroxylase (PAH) gene. It
is one of the most prevalent metabolic disorders, with a
high frequency (around 1/10,000) among Caucasians.
Biochemistry and genetics of PKU
The normal route for Phe metabolism is its hydroxylation
to tyrosine, catalyzed by PAH and requiring tetrahydro-
biopterin as a cofactor. The human PAH gene is located
on chromosome 12q23.2 and contains 13 exons. More
than 500 disease-causing mutations have been identified
in patients with PKU or hyperphenylalaninaemia (HPA),
67% of them being missense mutations. Most of them
result in severe enzyme deficiency generating the PKU
phenotype, but some are associated with a ”non-PKU
HPA” phenotype. Since the PAH gene is biallelic, most
patients are compound heterozygotes.
Clinical manifestations and pathogenesis of PKU
Untreated PKU is associated with an abnormal pheno-
type including growth failure, microcephaly, seizures
and intellectual impairment. The pathogenesis of these
abnormalities involves the neurotoxic effects of hyper-
phenylalaninaemia, which are linked to Tyr deficiency
(leading to a decrease in catecholamine neurotransmit-
ters), the effect of elevated Phe concentrations on trans-
port of other aminoacids across the blood brain barrier,
accumulation of toxic by-products of Phe metabolism.
Magnetic resonance imaging (MRI) has revealed white
matter lesions in the brain of adult PKU patients,
including hypomyelination and demyelination.
Diagnosis of PKU
Newborn screening programs exist in many countries,
based on the detection of a high blood Phe concentration.
Conventional PKU diagnosis is based on the aberrant
metabolic phenotype and the detection of disease causing
mutations at the PAH locus. Available methods include
Southern blotting, restriction enzyme digestion, gene
sequencing. PKU mutation analysis is particularly useful in
the detection of carriers, for prenatal diagnosis.
Treatment of PKU
The foundation of PKU treatment is a low Phe diet which
prevents the development of the neurological and psycho-
logical changes. It is recommended that dietary restriction
should be started early (within one month of birth) and be
followed for life. The existence of newborn screening pro-
grams and early dietary intervention allow children with
PKU to live relatively normal lives.
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